Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Table 2 Baseline characteristics of patients after propensity score matching, n (%)

Variables	Patients with OBBT (n = 32)	Patients without OBBT (n = 61)	P value	SMD
Gender
Male	23 (71.9)	39 (63.9)	0.440	0.171
Female	9 (28.1)	22 (36.1)
Age (range, years)	64.5 (47-80)	67 (29-81)	0.629	0.100
BMI (range, kg/m2)	22.8 (15.9-27.2)	21.8 (16.0-28.1)	0.757	0.066
Weight loss (range, %)	7.5 (0-33.3)	6.5 (0-23.80)	0.671	0.092
Smoking history
Yes	12 (37.5)	22 (36.1)	0.891	0.030
No	20 (62.5)	39 (63.9)
Drinking history
Yes	5 (15.6)	8 (13.1)	0.986	0.072
No	27 (84.4)	53 (86.9)
1Chronic disease
Yes	13 (40.6)	25 (41.0)	0.973	0.007
No	19 (59.4)	36 (59.0)
ECOG-PS
0	1 (3.1)	2 (3.3)	0.943	0.076
1	29 (90.6)	54 (88.5)
2	2 (6.3)	5 (8.2)
Primary tumor location
Body	12 (37.5)	26 (42.6)	0.891	0.105
Pylorus	9 (28.1)	16 (26.2)
Cardia	11 (34.4)	19 (31.1)
Cancer stage (AJCC 8th)
Stage III	6 (18.8)	13 (21.3)	0.771	0.064
Stage IV	26 (81.2)	48 (78.7)

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

OBBT: Overt bleeding before treatment; SMD: Standard mean difference; BMI: Body mass index; ECOG-PS: Eastern Corporative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.